The Prevalence, Genotype and Antimicrobial Susceptibility of High- and Low-Level Mupirocin Resistant Methicillin-Resistant Staphylococcus aureus by Park, Se Young et al.
SY Park, et al
32 Ann Dermatol
Received April 27, 2011, Revised July 5, 2011, Accepted for 
publication July 7, 2011
Corresponding author: Seok Don Park, M.D., Ph.D., Department of 
Dermatology, Wonkwang University Hospital, 344-2 Sinyong-dong, 
Iksan 570-711, Korea. Tel: 82-63-859-1601, Fax: 82-63-842-1895, 
E-mail: sdpark@wonkwang.ac.kr
This is an Open Access article distributed under the terms of the 
Creative Commons Attribution Non-Commercial License (http:// 
creativecommons.org/licenses/by-nc/3.0) which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, 
provided the original work is properly cited.
Ann Dermatol Vol. 24, No 1, 2012 http://dx.doi.org/10.5021/ad.2012.24.1.32
ORIGINAL ARTICLE
The Prevalence, Genotype and Antimicrobial 
Susceptibility of High- and Low-Level Mupirocin 
Resistant Methicillin-Resistant Staphylococcus aureus
Se Young Park, M.D.
1, Shin Moo Kim, Ph.D.
2, Seok Don Park, M.D., Ph.D.
1,3
1Department of Dermatology, Wonkwang University School of Medicine, 
2Department of Clinical Laboratory Science, Wonkwang Health 
Science University, 
3Institute of Wonkwang Medical Science, Wonkwang University School of Medicine, Iksan, Korea
Background: Mupirocin has been used for the treatment of 
skin infections and eradication of nasal carriage of methicil-
lin-resistant Staphylococcus aureus (MRSA). The increased 
use of this antibiotic has been accompanied by outbreaks of 
MRSA that are resistant to mupirocin. Objective: This study 
aims to determine the prevalence, genotype and antimicrobial 
susceptibility of mupirocin-resistant MRSA from 4 Korean 
hospitals. Methods: A total 193 MRSA clinical isolates were 
collected from four university hospitals. Antimicrobial sus-
ceptibility tests, including mupirocin, and pulsed-field gel 
electrophoresis (PFGE) pattern analysis were performed. 
Results: Overall, 27 of the 193 (14.1%) MRSA isolates were 
resistant to mupirocin. All of the (A) hospital isolates showed 
high-level (HL) mupirocin resistance and the low-level (LL) 
mupirocin resistant strains were from three other hospitals. 
The PFGE patterns of 16 mupirocin-resistant isolates were 
divided into 5 clusters (1-5), and the nine HL mupirocin- 
resistant isolates belonged to cluster 1. Both the HL and LL 
mupirocin-resistant MRSA isolates were susceptible to van-
comycin and rifampin, but they were resistant to ciproflo-
xacin, clindamycin and tetracycline. The erythromycin and 
fusidic acid resistance rates were different between the HL 
and LL resistant isolates. Conclusion: HL mupirocin-resistant 
isolates that could transfer this resistance to other bacteria 
were detected and these isolates were clonally related. The 
emergence of mupirocin resistant isolates emphasizes the 
importance of using antibiotics judiciously and carefully 
monitoring the prevalence of mupirocin resistance. (Ann 
Dermatol 24(1) 32∼38, 2012)
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INTRODUCTION
Mupirocin is a topical antibiotic that was originally isolated 
from  Pseudomonas fluorescens, and it inhibits bacterial 
protein synthesis by competitively binding to isoleucyl- 
tRNA synthetase (IleS). This drug is particularly effective 
against streptococci and staphylococci, including methicil-
lin-resistant Staphylococcus aureus (MRSA). Mupirocin is 
one of the most popular topical agents used for the treat-
ment of skin infection and eradication of nasal carriage of 
MRSA
1. The increased use of this antibiotic has been 
accompanied by outbreaks of MRSA that are resistant to 
mupirocin
2.
The mupirocin resistant strains are divided into two 
groups depending on the minimum inhibitory concentra-
tion (MIC) against mupirocin: low-level resistance (MIC=8
∼256μg/ml) and high-level resistance (MIC＞256μg/ 
ml). High-level mupirocin resistant strains are important in 
the clinical field because they are able to transfer resistance 
genes to other bacteria by plasmid conjugation, conse-
quently protecting these bacteria from being eradicated 
with mupirocin
3.
The use of mupirocin ointment has been increasing in High- and Low-level Mupirocin Resistant MRSA
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Fig. 1. Agarose gel electrophoresis of the amplified 372-bp DNA
fragments of the femA gene. The samples are lane M: a 100
bp size marker, lanes 1-9: mupirocin resistant MRSA, PC: femA-
positive control (S. aureus ATCC 33591) and NC: femA-negative
control (S. epidermidis ATCC 2228). MRSA: methicillin-resistant
Staphylococcus aureus.
Fig. 2. Agarose gel electrophoresis of the amplified 554-bp DNA
fragments of the mecA gene. The samples are lane M: a 100
bp size marker, lanes 1-9: mupirocin resistant MRSA, PC: mecA-
positive control (ATCC 33591) and NC: mecA-negative control
(ATCC 25923). MRSA: methicillin-resistant Staphylococcus aureus.
Fig. 3. Agarose gel electrophoresis of the amplified 1.6 kb DNA
fragments of the mupA gene. The samples are lane M: a 1-kb 
size marker, lanes 1-2, 4-5, 9-11: high-level mupirocin resistant
MRSA, PC: mupA-positive control (KCKC 6129), and NC: mupA-
negative control (ATCC 25923). MRSA: methicillin-resistant Sta-
phylococcus aureus.
Fig. 4. Agarose gel electrophoresis of the amplified 1.6 kb DNA
fragments of the mupA gene. The samples are lane M: a 1-kb 
size marker, lanes 15, 21-26: low-level mupirocin resistant MRSA,
PC: mupA-positive control (KCKC 6129) and NC: mupA-negative
control (ATCC 25923). MRSA: methicillin-resistant Staphylococ-
cus aureus.
Korea, but there are only a few studies about mupirocin 
resistance in MRSA
4-6. Therefore, we measured the preva-
lence, genotype and antimicrobial susceptibility of mupiro-
cin-resistant MRSA from four Korean university hospitals. 
MATERIALS AND METHODS
Bacterial isolates
A total of 193 MRSA isolates were collected from the cli-
nical cultures taken from patients at four Korean university 
hospitals (A∼D) from April 2008 to July 2009. The speci-
mens originated from the skin, pus, blood, central venous 
catheter tip, sputum, tracheal tip, urine, and wound. Of 
these, 103 strains were from (A) hospital and 30 strains 
were from the other 3 hospitals, respectively. All the 
MRSA isolates were randomly collected from each of the 
hospitals. 
Antimicrobial susceptibility test
The susceptibility to antimicrobial agents was determined 
by agar dilution tests, according to the guidelines provided 
by the Clinical and Laboratory Standards Institute (CLSI). 
Eight antimicrobial agents were tested: ciprofloxacin, clin-
damycin, erythromycin, fusidic acid, mupirocin, rifampin, 
tetracycline and vancomycin. S. aureus ATCC 33591 was 
used as a control strain.
Briefly, serial two-fold dilutions of the antibiotics were 
prepared in Muller-Hinton agar (Difco Laboratories, Det-
roit, MI, USA). The strains were subcultured on tryptic soy 
agar (Difco Laboratories), suspended in tryptic soy broth 
(Difco Laboratories) and adjusted to the turbidity of a 0.5 
McFarland standard. Next, the suspension was diluted 1：
10 and inoculated on each plate coated with antibiotic 
containing media by a Steer replicator. The inoculated 
plates were incubated at 35
oC for 24 hr. The lowest 
concentration of antibiotic that inhibits the visible growth 
of an organism was regarded as the MIC, and growth of 
one isolate was ignored. The MIC50 and MIC90 were the 
MICs that were required to inhibit 50% and 90% of the 
organisms, respectively. The MIC determination was 
evaluated according to the CLSI guidelines
7.
Detection of the femA,  mecA and mupA genes by 
polymerase chain reaction (PCR)
All the isolates were confirmed to be S. aurues and MRSA 
by detection of the femA and mecA genes using a PCR 
assay. The high level mupirocin resistant strains were also 
confirmed by detection of the mupA gene (Fig. 1∼4). Three 
primer pairs were used for the detection of the femA, 
mecA and mupA genes. For femA gene detection, forward 
primer (5’-CATGATGGCGAGATTACAGG-3’) and reverse 
primer (5’-CGCTAAAGGTACTAACACACGG-3’) with a fr-SY Park, et al
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agment of 372 bp were used
8. For mecA gene detection, 
forward primer (5’-ATGAGATTAGGCATCGTTCC-3’) and 
reverse primer (5’-TGGATGACAGTACCTGAGCC-3’) with 
a fragment of 554 bp were used
9. For mupA gene detec-
tion, forward primer (5’-CCCATGGCTTACCAGTTGA-3’) 
and reverse primer (5’-CCATGGAGCACTATCCGAA-3’) 
with a fragment of 1.6 kb were used
10.
Prior to DNA extraction, frozen bacteria were subcultured 
twice onto Mueller-Hinton agar plates. For extraction, one 
to five bacterial colonies were suspended in 50μl of cell 
lysis buffer (Genotek Co., Daejeon, Korea) and this was 
heated at 100
oC for 10 min. After centrifugation at 12,000 
rpm for 10 min, 2μl of the supernatant was used for DNA 
extraction. The PCR reactions were performed using a Pri-
mer Mix Kit (Genotek Co.). The thermal cycler (GeneAmp 
PCR system 9700, Perkin-Elmer Cetus, Foster City, CA, 
USA) was programmed with the following parameters: 
pre-denaturation at 95
oC for 15 min, 30 cycles of 
denaturation at 94
oC for 30 s, annealing at 68
oC for 90 s, 
extension at 72
oC for 90 s and a final extension at 72
oC for 
10 min. The amplified products were run on a 2% agarose 
gel for 20 min at 200 volts and visualized with ethidium 
bromide.
Pulsed-field gel electrophoresis (PFGE)
A total of 16 strains of mupirocin resistant MRSA (10 isola-
tes with high-level resistance and 6 isolates with low-level 
resistance) were used for PFGE
11. The high-level resistant 
strains were from (A) hospital. For the low-level strains, 2 
strains were from (B) hospital, 3 strains were from (C) 
hospital and one strain was from (D) hospital. 
Each isolate was inoculated into 3 ml Luria-Vertani broth 
(Difco Laboratories) and incubated at 37
oC overnight. The 
concentration of the cell suspensions were adjusted with 
saline using a spectrophotometer to an absorbance of 0.3
∼0.25 at 610 nm. After adjustment, 1 ml of the cell 
suspension was centrifuged at 14,000 rpm for 5 min and 
the supernatant was aspirated. The pellet was washed 
once in 1 ml of Tris-EDTA (TE) buffer (10 mM Tris HCl, 1 
mM EDTA [pH 8]) and centrifuged again. The washed 
cells were resuspended in 50μl of lysis II buffer (6 mM 
Tris-HCl, pH 8.0, 1 M NaCl, 100 mM EDTA, 0.5% 
Brij-58, 0.2% sodium deoxycholate, 0.5% sodium lauroyl-
sarcosine) and equilibrated at 37
oC for 15 min. Fifty micro-
liters of 2% low-melting-pint agarose and 2μl of 100 units 
lysostaphin were added to the cell suspension, gently 
mixed and dispensed into a plug mold. The plugs were 
allowed to solidify in the refrigerator at 4
oC for 5 min. The 
plugs were placed into a tube containing 250μl of lysis I 
buffer (50 mM Tris-HCl, pH 7.4, 100 unit lysostapin, lyso-
zyme 1 mg/ml) and the cells in the plug were lysed for 1 h 
at 37
oC. Then the lysis I buffer were removed and repla-
ced with 250μl of lysis II buffer at 37
oC for 1 h. The lysis 
II buffer was removed and 250μl of proteinase K buffer 
(0.5 M EDTA, 25 unit/ml proteinase K) was added and this 
was incubated at 50
oC overnight. The TE washings were 
repeated 3 more times. 
For electrophoresis, the plug was cut into small slices (2 
by 5 mm) and these were placed in 125μl of a total 
restriction enzyme mixture that contained 20 U of SmaI 
(Sib Enzyme Ltd, Novosibirk, Russia). After 2 h incubation 
at 25
oC with shaking at 140 rpm, the chromosomal restric-
tion fragment patterns were analyzed by loading the trim-
med slices of the plug into a well of SeaKem 1% agarose 
gel. The running gel was prepared in 0.5×TBE buffer (Bio- 
Rad Laboratories, Inc., Hercules, CA, USA). Electropho-
resis was performed with a CHEP-DR III (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). The running parameters 
were an initial pulse of 5 s, a final pulse of 40 s, 200 V, 20 
hrs and 12∼14
oC. After the electrophoresis run was com-
pleted, the gel was stained with 0.5μg/ml ethidium bro-
mide for 20 min and destained in fresh distilled water for 
20 min.
The gels were photographed and digitalized with a GelDoc 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA). The ima-
ges were stored electronically as TIFF files. The restriction 
pattern was analyzed with the GelCompar II program 
(version 4.5; Applied Maths, Sint-Martens-Latem, Belgium) 
using the Dice coefficient, and cluster analysis of the 
similarity matrices was performed by the unweighted pair 
group method using the arithmetic average with 0.75% of 
tolerance
12,13. The similarity cut-off value was 99%.
RESULTS
Prevalence of mupirocin resistant MRSA
Of the total 193 clinical isolates of MRSA from the four 
university hospitals, 27 (14.1%) were mupirocin resistant 
(Table 1). Of these, 11 (5.7%) were found to have high- 
level resistance to mupirocin and all of them were from 
(A) hospital. The low-level strains were composed of 2, 13 
and 1 isolates from (B), (C) and (D) hospitals, respectively. 
Antimicrobial susceptibility tests of the mupirocin 
resistant MRSA
The antimicrobial susceptibility test results for the mupi-
rocin resistant MRSA isolates are summarized in Table 2. 
The MICs of the high-level mupirocin resistant MRSA 
ranged from 512 to ≥1,024μg/ml, and the MIC50 and 
MIC90 were ≥1,024μg/ml, respectively. But for the low- 
level mupirocin resistant strains, the MICs ranged from 16 
to 32, and the MIC50 and MIC90 was 16μg/ml in both High- and Low-level Mupirocin Resistant MRSA
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Table 1. Rates of mupirocin resistant MRSA isolates in four 
Korean hospitals




A 103 11* 10.7
B 3 0  2 6 . 7
C  30 13 43.3
D 3 0  1 3 . 3
Total 193 27 14.1
MRSA: methicillin-resistant Staphylococcus aureus. *High level
mupirocin resistant MRSA isolates.
Table 2. Antimicrobial susceptibilities of the 11 high-level and 16 low-level mupirocin resistant MRSA isolates




High level (n=11) Mupirocin 512∼≥1,024 ≥1,024 ≥1,024 100
Ciprofloxacin 32∼≥128 32 64 100
Clindamycin 128 128 128 100
Tetracycline 64 64 64 100
Erythromycin ≥128 ≥128 ≥128 100
Fusidic acid ≤0.25∼≥128 ≥128 ≥128 90
Rifampin ≤0.5 ≤0.5 ≤0.5 0
Vancomycin 0.5∼10 . 5 0 . 5 0
Low level (n=16) Mupirocin 16∼32 16 16 100
Ciprofloxacin 16∼≥128 32 64 100
Clindamycin ≥128 ≥128 ≥128 100
Tetracycline 16∼64 16 32 100
Erythromycin ≤0.5∼≥128 ≥128 ≥128 24
Fusidic acid ≤0.25∼≥128 ≥128 ≥128 77
Rifampin ≤0.5∼≥128 ≤0.5 2 6
Vancomycin 0.5∼111 0
MRSA: methicillin-resistant Staphylococcus aureus, MIC: minimum inhibitory concentration.
Fig. 5. A dendrogram generated with
the Gelcompar II program showing 
the five PFGE types (1-5) of SmaI- 
restricted chromosome DNA of the 
16 mupirocin-resistant MRSA isolates.
H1-H10: isolates with high-level mu-
pirocin resistance, L16-21: isolates 
with low-level mupirocin resistance.
PFGE: pulsed-field gel electrophore-
sis, MRSA: methicillin-resistant Sta-
phylococcus aureus.
cases. Compared with the MIC90 among the high-level 
resistant strains, rifampin and vancomycin showed high 
antimicrobial activity and the MICs were ≤0.5μg/ml and 
0.5μg/ml, respectively. The MICs of ciprofloxacin and 
tetracycline were 64μg/ml, respectively and those for 
erythromycin and fusidic acid were ≥128μg/ml, respec-
tively. For the low-level mupirocin resistant MRSA strains, 
vancomycin showed the highest antimicrobial activity 
(MIC=1μg/ml) and this was followed by rifampin (2μg/ 
ml), tetracycline (32μg/ml) and ciprofloxacin (64μg/ml). 
The MICs of clindamycin, erythromycin and fusidic acid 
were ≥128μg/ml, respectively.
The high-level mupirocin resistant MRSA strains were 
susceptible to rifampin and vancomycin, but 90% were 
resistant to fusidic acid, and 100% were resistant to 
ciprofloxacin, clindamycin, tetracycline and erythromycin. 
While the low-level mupirocin resistant MRSA strains 
were susceptible to vancomycin, 6% were resistant to 
rifampin, 24% were resistant to erythromycin, 77% were 
resistant to fusidic acid and 100% were resistant to SY Park, et al
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ciprofloxacin, clindamycin and tetracycline.
Genotyping the mupirocin resistant MRSA using the 
PFGE patterns
The PFGE patterns of the genomic DNA of the 16 strains 
of mupirocin resistant MRSA were classified into five 
clusters (Fig. 5). Of the 10 high-level resistant strains from 
(A) hospital, 9 (H1-H7, H9-H10) were classified in cluster 
1 with 92% similarity. Among these, H6 and H10, H1-4 
and H9, and H5 and H7 were the same clones. The H8 
strain was in cluster 4 with 72% similarity. Of the 6 
low-level resistant strains, L16-L18 from (B) hospital were 
classified in cluster 2 and they were the same clone with 
100% similarity. The L19 and L20 from (A) hospital were 
in cluster 4 with 93% similarity, and L21 from (D) hospital 
was in cluster 5 with 79% similarity.
DISCUSSION
Mupirocin is a topical antibiotic that shows a high level of 
activity against streptococci and staphylococci, and certain 
gram-negative bacteria, including Haemophilus influenzae 
and Neisseria gonorrhoae, but it is much less active again-
st most gram-negative bacilli and anaerobes
1. Therefore, it 
has been used to treat skin infection and to eradicate 
MRSA. Mupirocin was introduced into clinical practice in 
1985 and the use of mupirocin ointment has been pro-
gressively increasing worldwide.
Clinical isolates resistant to mupirocin were first reported 
in 1987, and the resistance rate has been increasing
14. 
Prolonged use and frequent use of mupirocin were thought 
to be the most important factors associated with the in-
crease of mupirocin resistance
3,15. A Canadian study by 
Simor et al.
2 reported an increase in mupirocin resistance 
among MRSA over time. From 1995 to 1999, the propor-
tions of MRSA strains with high- and low-level mupirocin 
resistance were 1.6% and 6.4%, respectively, whereas from 
2000 to 2004, the resistant rates were 7.0% and 10% 
respectively. Pérez-Fontán et al.
16 reported the emergence 
of mupirocin-resistant S. aureus in peritoneal dialysis pati-
ents who applied mupirocin over 10 years. From 1990 to 
1996, there were no mupirocin resistant strains, but they 
increased to 8.3% from 1997 to 1998, and to 12.4% from 
1999 to 2000. According to Wise and Johnson
17, the 
mupirocin resistance rate was 8.3% in a dermatological 
hospital, while it was 0.2% in the nearby general hospitals 
over the same period.
In Korea, topical mupirocin has been used since 1994 to 
eradicate staphylococcal infection in hospitals and the use 
of mupirocin has been dramatically increasing. However, 
there has been very little awareness and research about 
mupirocin resistance. The study conducted in Korea up to 
1999 failed to detect mupirocin resistant strains
18. Yet Yun 
et al.
4 first identified 16 high-level mupirocin resistant 
isolates in 2003 and the prevalence of mupirocin resis-
tance was 5%. In a study from long-term-care facilities in 
Korea, the rate of mupirocin resistance was 11.3% (6.1% 
high-level mupirocin resistance and 5.2% low-level mupi-
rocin resistance)
5. Another study carried out at intensive 
care units reported that the mupirocin resistance rate was 
25.3% and all the isolates showed low-level resistance. In 
our study, the prevalence of mupirocin resistance was 
14.1%. The 5.7% of the isolates were high-level resistant 
strains (11/193) and all of them were from (A) hospital. 
The low-level resistant strains were from the other three 
hospitals. Also, the prevalence of mupirocin resistance of 
(C) hospital was 43.3%, which is much higher than that of 
the other hospitals, and the reason for this was thought to 
be there were more dermatological samples from (C) 
hospital. 
Mupirocin resistance is divided into two groups: low-level 
resistance (MIC=8∼256μg/ml) and high-level resistance 
(MIC＞256μg/ml). Low-level mupirocin resistance is due 
to point mutation in the chromosomally encoded native 
IleS gene, whereas high-level resistance is related to the 
acquisition of a plasmid containing a modified additional 
IleS-2 gene mupA
3,4. However, the mupA gene was detec-
ted in the low-level mupirocin resistant strains by western 
blot analysis in a small case study
10. It is also possible that 
high- and low-level mupirocin resistance are mediated by 
different, but closely related genes that hybridize with the 
mupA probe, so further studies are needed to resolve this 
issue.
Low-level mupirocin resistant strains are not considered to 
have clinical significance because the concentration of 
mupirocin in the 2% ointment (20,000μg/ml) exceeds the 
MICs of the low-level mupirocin resistant strains, so low- 
level mupirocin resistant strains can be treated by topical 
mupirocin
19. On the contrary, high-level mupirocin resis-
tant strains that can not be treated by mupirocin are more 
clinically important. Fortunately, low-level strains have so 
far been more frequently isolated than high-level strains. 
In our study, the prevalence of low-level mupirocin resis-
tance (8.3%) was higher than the prevalence of high-level 
resistance (5.7%)
2,10,20. However, high-level mupirocin 
resistant strains have been increasing in prevalence recen-
tly. Also, the mupirocin resistance rates were higher for 
the methicillin-resistant isolates than for the methicillin- 
susceptible isolates
4,21. Chaves et al.
21 detected a much 
higher percentage of mupirocin resistance among the 
isolates of MRSA (14.8%) than among the isolates of 
methicillin-susceptible  S. aureus (0.6%). Therefore, the High- and Low-level Mupirocin Resistant MRSA
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evaluation of mupirocin resistance, and especially high- 
level resistance, is very important in MRSA isolates. 
High-level mupirocin resistant strains have an additional 
mupA gene in a plasmid that can be transferred to other 
strains by plasmid conjugation
22,23. Bastos et al.
23 showed 
that mupirocin resistance is transferred from mupirocin 
resistant strains of S. aureus to mupirocin susceptible S. 
aureus via a conjugative plasmid. Furthermore, this plas-
mid was transferred between S. aureus and Staphylococ-
cus epidermidis. This result indicates the possibility of 
horizontal transfer of the conjugative plasmid among 
Staphylococcus species and this suggests that Staphylo-
coccus epidermidis could be a reservoir of this plasmid. 
This enables the wide spread of mupirocin resistance. 
Further, the mupA gene may co-transfer with other antibac-
terial resistance, such as that against triclosan, tetracycline 
and trimethoprim
3.
PFGE is the most widely used genotyping or genetic 
fingerprinting tool, although it requires technical skill, a 
long processing time and expensive instruments. It is 
commonly considered the gold standard method for 
epidemiologic typing and the determination of genetic 
relatedness
11,24. Yoo et al.
5 showed 20 of 25 high-level 
and 20 of 21 low-level mupirocin resistant S. aureus from 
eight long-term-care facilities belonged to the same PFGE 
groups. A study by Chaves et al.
21 also identified that 13 
of 14 high-level mupirocin resistant strains showed the 
same PFGE band patterns. These results indicate that 
clonal transmission of mupirocin-resistant S. aureus occur-
red in hospitals. In our study, 9 of 10 high-level mupirocin 
resistant MRSA isolates from (A) hospital and 5 of 6 low- 
level resistant isolates (2 from (A) hospital, 3 from (B) hos-
pital) belonged to the same PFGE group.
The antimicrobial susceptibility of the mupirocin resistant 
strains can vary depending on different studies. A study 
conducted on 4980 MRSA strains showed mupirocin- 
resistant strains were more likely to be resistant to fusidic 
acid and to be susceptible to tetracycline, trimethoprim- 
sulfamethoxazole and ciprofloxacin as compared to that of 
the mupirocin-susceptible strains
2. Yoo et al.
5 showed all 
the mupirocin resistant S. aureus were resistant to oxacil-
lin, penicillin and erythromycin and they were susceptible 
to ampicillin and vancomycin. In our study, the mupirocin 
resistant MRSA isolates were susceptible to vancomycin 
and rifampin, and they were resistant to ciprofloxacin, 
clindamycin and tetracycline. Compared to the low-level 
mupirocin resistant strains, the high-level mupirocin resis-
tant strains were more resistant to erythromycin and fusi-
dic acid.
Several agents have been shown to have activity against 
mupirocin resistant S. aureus
3. These include azelaic acid, 
nitrofurazone and silver sulphadiazine. Maple et al.
25 sho-
wed that the concentrations of azelaic acid, nitrofurazone 
and silver sulphadiazine close to the MIC were bacteri-
cidal, but mupirocin was only bactericidal at concentra-
tions substantially greater than the MIC.
Prolonged use and frequent usage of mupirocin appear to 
be the most important factors for increasing mupirocin 
resistance. Riley et al.
26 recommended less than 10 days 
treatment and at least 1 month between treatment. 
The increasing number of reports of high-level mupirocin 
resistance could mean the potential loss of one of the 
major treatment methods for controlling MRSA. Therefore, 
mupirocin treatment should be used cautiously and judi-
ciously. Careful monitoring of mupirocin usage and test-
ing of S. aureus, including MRSA, for mupirocin resistance 
seems to be indicated. 
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